Browsing by Subject "Companion diagnostics"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Current Progress in CAR-T Cell Therapy for Solid Tumors
    (Ivyspring, 2019-09-07) Ma, Shuo; Li, Xinchun; Wang, Xinyue; Cheng, Liang; Li, Zhong; Zhang, Changzheng; Ye, Zhenlong; Qian, Qijun; Pathology and Laboratory Medicine, School of Medicine
    Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells.